Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Orca-Q in Relapsed/Refractory High-Risk Multiple Myeloma
NCT07759102Phase 1Not yet recruiting
- Sponsor
- University of California, Davis
- Start
- Sep 2026
- Primary completion
- Sep 2032
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Orca-Q in multiple myeloma (MM), sponsored by University of California, Davis. Primary endpoint: Incidence of primary graft failure without grade II-IV acute graft-versus-host disease (GVHD) at 30 days. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
Orca-Q
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT07759102.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07759102.